Medline (NASDAQ:MDLN) Major Shareholder Private Ltd Gic Sells 590,284 Shares

Medline (NASDAQ:MDLN) major shareholder Private Ltd Gic sold 590,284 shares of Medline stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $35.58, for a total transaction of $21,002,304.72. Following the completion of the sale, the insider owned 24,402,482 shares of the company’s stock, valued at $868,240,309.56. This trade represents a 2.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Private Ltd Gic also recently made the following trade(s):

• On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The stock was sold at an average price of $35.33, for a total value of $9,609,548.02.
• On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The shares were sold at an average price of $35.60, for a total value of $70,367,600.80.

Medline Price Performance

Shares of MDLN opened at $35.04 on Wednesday. The company has a market cap of $46.03 billion and a P/E ratio of 109.50. The firm’s 50 day moving average price is $38.21 and its 200 day moving average price is $41.57. Medline has a fifty-two week low of $32.81 and a fifty-two week high of $50.88. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66.

Medline (NASDAQ:MDLN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.18. The company had revenue of $7.68 billion for the quarter. On average, research analysts forecast that Medline will post 1.49 earnings per share for the current fiscal year.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: TD Cowen maintained a Buy rating and set a $45 price target, implying substantial upside from recent levels. The firm cited Medline’s strong cash flow and longer-term growth outlook. TD Cowen Medline rating
• Positive Sentiment: Tigress Financial lowered its price target from $62 to $55 but retained a Buy rating. The revised target still represents significant potential upside, suggesting the analyst views recent weakness as excessive. Benzinga analyst action
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures include an apparent “NaN” calculation, the data may be incomplete or unreliable and offers little actionable insight for investors.
• Negative Sentiment: Wells Fargo cut its price target from $45 to $34 and changed its stance to Equal Weight. The new target is slightly below the recent trading level, signaling limited near-term upside in the firm’s view. Wells Fargo Medline price target
• Negative Sentiment: Major shareholder Private Ltd Gic sold approximately 590,284 shares worth $21.0 million, reducing its ownership by 2.36%. While the investor still holds a substantial stake, the sale may add modest pressure or raise concerns about insider sentiment. SEC ownership filing
• Negative Sentiment: Law firm Kaplan Fox announced an investigation into potential securities-law violations involving Medline. The announcement does not establish wrongdoing, but it introduces legal and reputational risk and may weigh on investor confidence. Kaplan Fox Medline investigation

Hedge Funds Weigh In On Medline

A number of hedge funds and other institutional investors have recently made changes to their positions in MDLN. Carlyle Group Inc. purchased a new stake in Medline during the 4th quarter valued at approximately $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new position in shares of Medline in the fourth quarter valued at approximately $4,179,591,000. Vanguard Group Inc. acquired a new position in shares of Medline in the fourth quarter valued at approximately $793,278,000. Morgan Stanley purchased a new stake in shares of Medline during the fourth quarter worth approximately $636,807,000. Finally, Capital Research Global Investors acquired a new stake in shares of Medline during the fourth quarter worth $620,937,000.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. BMO Capital Markets reissued an “outperform” rating and issued a $47.00 target price on shares of Medline in a research report on Thursday, August 6th. Stifel Nicolaus reduced their price objective on Medline from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Tigress Financial decreased their price objective on Medline from $62.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday. William Blair restated an “outperform” rating on shares of Medline in a research report on Thursday, June 4th. Finally, Sanford C. Bernstein cut their target price on shares of Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.69.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.